NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Vivos Therapeutics, Inc. VVOS
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$17.4M
▲ 16.0% vs FY2024
EPS · FY25
$-2.07
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-655.0%
Net margin · FY25
-121.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 17.4M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 121 cents on every revenue dollar this year.
Per share
USD -2.07
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-655.0%
Return on equity, FY2025
ROE
Operating margin-114.1%
Net margin-121.4%
Return on assets-104.7%
Each USD of equity lost 655 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.9%
+5.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 25.2M
total assets, end of FY2025
Total assetsUSD 25.2M
EquityUSD -1.5M
CashUSD 2.0M
Gross debtUSD 8.8M
Net debtUSD 6.8M
Current ratio0.24×
Net debt stands at -456% of equity.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.07
−2.22
−11.14
−25.90
−0.96
−1.40
−0.95
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−655.0
−266.3
−521.2
−157.2
−95.6
−172.6
·
Shares out B
0.01
0.01
0.00
0.00
0.02
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 3 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed